Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04874311 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Study acronym: TRUST
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Study sites: 8 to 6
    v8
  2. Notable Primary completion date: Sep 2024 to Jan 2027
    • Study completion date: Mar 2025 to Jul 2027
    v7
  3. Minor Site details revised at 2 of 8 sitesv6
  4. Notable Start date: Nov 1, 2021 to Mar 1, 2022
    • Primary completion date: May 2024 to Sep 2024
    • Study completion date: Dec 2024 to Mar 2025
    • Site details revised at 7 of 8 sites
    v5
  5. Minor Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 8 of 8 sites
    v3
  2. Minor Start date: Dec 2021 to Nov 1, 2021v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
1,026 trials monitored
See 67 trials at risk
This study encompasses two multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trials to assess the antitumor activity of bintrafusp alfa in association with doxorubicin
Trial Details
NCT Number NCT04874311
Lead Sponsor Institut Bergonié
Collaborators: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Conditions
(from sponsor)
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
Related terms Neoplasm Metastasis, Sarcoma, Tertiary Lymphoid Structures
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov